First Wave BioPharma, Inc.
Index- P/E- EPS (ttm)-11.19 Insider Own1.10% Shs Outstand12.92M Perf Week-20.36%
Market Cap5.82M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float- Perf Month-51.33%
Income-84.50M PEG- EPS next Q-0.53 Inst Own3.40% Short Float- Perf Quarter-74.80%
Sales- P/S- EPS this Y35.50% Inst Trans-21.57% Short Ratio0.10 Perf Half Y-82.80%
Book/sh-0.61 P/B- EPS next Y68.60% ROA-604.00% Target Price20.00 Perf Year-96.18%
Cash/sh0.45 P/C0.71 EPS next 5Y- ROE- 52W Range0.28 - 9.70 Perf YTD-77.85%
Dividend- P/FCF- EPS past 5Y15.80% ROI- 52W High-96.70% Beta1.88
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin- 52W Low14.29% ATR0.06
Employees17 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)26.58 Volatility15.57% 14.37%
OptionableNo Debt/Eq- EPS Q/Q85.60% Profit Margin- Rel Volume0.15 Prev Close0.34
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume929.55K Price0.32
Recom2.70 SMA20-21.76% SMA50-54.94% SMA200-85.11% Volume138,082 Change-5.83%
May-17-22 07:00AM  
Apr-29-22 04:30PM  
Apr-27-22 07:00AM  
Mar-31-22 08:15AM  
Mar-28-22 04:23PM  
Mar-22-22 07:00AM  
Mar-08-22 07:00AM  
Mar-03-22 07:00AM  
Mar-02-22 05:00PM  
Mar-01-22 07:00AM  
Feb-28-22 08:01AM  
Feb-07-22 07:30AM  
Jan-17-22 10:30AM  
Jan-14-22 11:25AM  
Jan-13-22 07:00AM  
Jan-07-22 09:16AM  
Jan-06-22 07:00AM  
Jan-04-22 07:00AM  
Dec-27-21 02:00PM  
Dec-23-21 11:45AM  
Dec-17-21 09:06AM  
Dec-13-21 07:00AM  
Dec-09-21 07:00AM  
Dec-06-21 07:00AM  
Nov-30-21 07:00AM  
Nov-16-21 07:00AM  
Oct-21-21 07:30AM  
Oct-19-21 09:24AM  
Oct-14-21 09:00AM  
Oct-12-21 08:30AM  
Oct-04-21 11:45AM  
Oct-01-21 12:30PM  
Sep-28-21 08:00AM  
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.